羟基脲治疗镰状细胞病的真实世界ESCORT-HU队列研究
ESCORT-HU是一项IV期观察性队列研究,纳入1906例镰状细胞病患者(55%为成人),中位随访45个月。羟基脲治疗12个月内血管闭塞危象、急性胸部综合征、住院和输血需求较入组前一年显著下降,未发现新的毒性,妊娠未观察到新生儿畸形,总体获益风险比良好。
要点
- 羟基脲可显著减少镰状细胞病患者的血管闭塞危象、急性胸部综合征、住院和输血需求
- 最常见不良反应为中性粒细胞减少和血小板减少,未发现新的毒性
- 101例女性125次妊娠中未观察到新生儿畸形,1例致命性MDS不能排除与羟基脲相关
核心结论
- 羟基脲在儿童和成人镰状细胞病患者中获益风险比良好。
研究设计与样本
- ESCORT-HU为IV期观察性队列研究,纳入1906例参与者,55%为成人,中位随访45个月,共7309患者年。
主要发现
- 最常见血红蛋白基因型为HbSS(84.7%)和HbSβ+(7.0%)。
- 治疗1年后羟基脲剂量儿童为20.6 mg/kg/d,成人为16.3 mg/kg/d。
- 相对入组前一年,治疗12个月内持续时间>48小时的血管闭塞发作、急性胸部综合征发作、住院和需要输血的患者百分比均显著下降。
- 最常见不良反应为中性粒细胞减少和血小板减少,未发现新的羟基脲毒性。
- 101例女性报告125次妊娠,新生儿未观察到畸形;男性患者伴侣有12次妊娠;报告1例致命性骨髓增生异常综合征,不能排除与羟基脲的因果关系。
临床怎么用
- 真实世界数据支持羟基脲用于儿童和成人严重型镰状细胞病以预防血管闭塞危象。
- 治疗期间应监测中性粒细胞和血小板减少等不良反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several controlled studies have evidenced good efficacy and short-term and mid-term safety profiles for hydroxyurea (HU), which has become the cornerstone for prevention of sickle-cell disease (SCD)-related vaso-occlusive crises. However, there are few large-scale reports on its long-term use and certain caregivers and patients have concerns about its safety. Following the licensing of HU in Europe for children and adults with severe forms of SCD, ESCORT-HU was designed as a Phase IV observational cohort study. It included 1906 participants, of whom 55% were adults. The most common hemoglobin (Hb) genotypes were HbSS (84.7%) and HbSβ+ (7.0%). The median duration of follow-up was 45 months, for a total of 7309 patient-years of observation. The dose of HU after 1 year was 20.6 mg/kg/d for children and 16.3 mg/kg/d for adults. There was a statistically significant decrease in the number of vaso-occlusive episodes lasting >48 h, acute chest syndrome episodes, hospitalizations, and the percentage of patients requiring blood transfusions within the first 12 months relative to the year before enrolment. Neutropenia and thrombocytopenia were the most commonly reported adverse effects. No new HU toxicity was identified. Overall, 125 pregnancies were reported in 101 women and no malformations were observed in the neonates. There were 12 pregnancies for partners of male patients treated with HU. One case of fatal myelodysplastic syndrome was reported, for which a causal association with HU could not be excluded. This cohort study of patients with SCD highlights the positive benefit-to-risk ratio of HU in children and adults.
引用
- de Montalembert M, Voskaridou E, Oevermann L, et al. Real-Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT-HU cohort study. Am J Hematol. 2021. PMID: 34224583. doi:10.1002/ajh.26286
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。